The US took a step closer to approving the Pfizer/BioNTech Covid-19 vaccine on Thursday, after a committee of experts recommended that the Food and Drug Administration grant it an emergency authorisation.
The majority of scientists on the Vaccines and Related Biological Products Advisory Committee agreed that the benefits of the Pfizer/BioNTech vaccine outweighed its risks for use in people 16 years of age and older. After an occasionally heated debate, 17 members voted in favour, while four voted against and one abstained.
The vote clears the way for a final decision from the FDA, which could come in the “next couple of days”, according to Marion Gruber, the director of the FDA’s vaccine research office.
您已閱讀20%（712字），剩余80%（2850字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。